MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Dyskinesias"

  • 2018 International Congress

    Dyskinesia management in COMT-naïve patients starting adjunctive therapy with opicapone: The BIPARK-I double-blind experience

    J. Pagonabarraga, E. Tolosa, J. Ferreira, A. Lees, E. Arbe, J. Rocha, P. Soares-da-Silva (Barcelona, Spain)

    Objective: To elucidate which levodopa-treated COMT-naïve Parkinson’s Disease (PD) patients were at higher risk for developing dyskinesia when starting opicapone (OPC) 50mg or entacapone (ENT).…
  • 2018 International Congress

    Final MDS-UPDRS, Part IV Results of the EASE LID 2 Study: Long Term, Open-Label Study of ADS-5102 for Dyskinesia in Parkinson’s disease (PD) patients

    R. Hauser, R. Pahwa, C. Tanner, W. Oertel, R. Johnson, L. Felt, MJ. Stempien, R. Patni (Tampa, FL, USA)

    Objective: An objective of this study was to evaluate the long-term duration of ADS-5102 effect on dyskinesia as assessed by the Unified Parkinson’s Disease Rating…
  • 2018 International Congress

    Polymorphisms of glutamatergic system genes are associated with levodopa-induced dyskinesia in Parkinson’s disease

    I. Mironova, A. Latypova, I. Zhukova, O. Izhboldina, E. Kolupaeva, N. Zhukova, S. Ivanova (Tomsk, Russian Federation)

    Objective: We aimed to study the association between glutamatergic system gene polymorphisms (SLC1A2 – gene, coding excitatory acids transporter, and GRIN2A gene, coding a subunit…
  • 2018 International Congress

    The anti-dyskinetic effect of the clinically-available 5-HT3 receptor antagonist granisetron in the 6-OHDA-lesioned rat model of Parkinson’s disease

    C. Kwan, I. Frouni, D. Bedard, A. Hamadjida, P. Huot (Montreal, QC, Canada)

    Objective: To determine the effect of the serotonin 3 (5-HT3) receptor antagonist granisetron, a clinically-available anti-emetic, on L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesia. Background: Dopamine replacement with L-DOPA…
  • 2018 International Congress

    Intraoperative Electromyography can optimize pallidotomy for Parkinson’s disease and dystonias

    P. Brainer, A. Campos, A. Brainer, J. Brainer, P. Brainer, P. Coutinho, C. Lima, S. Laurentino, R. Bandin, M. Andrade (Recife, Brazil)

    Objective: The aim of this study is show our experience in use intraoperative electromyography during stereotactic pallidotomy for Parkinson’s disease and dystonia, to help care…
  • 2018 International Congress

    Novel population-specific mutationsin PINK1 and Parkin genes from India

    A. Kishore, M. Sturm, A. Asok, C. Schulte, D. KP, S. Krishnan, O. Riess, M. Sharma (Trivandrum, India)

    Objective: To look for novel and population-specific genes for PD in 50 Indian families with Parkinson's disease Background: Till date, 138 mutations in PINK1 and…
  • 2018 International Congress

    Liquid sinemet in the management of complex motor fluctuations in advanced Parkinson’s Disease

    C. Sung, M. Danoudis, R. Iansek (Melbourne, Australia)

    Objective: To investigate the effectiveness of Levodopa carbidopa ascorbic acid solution (LCAS) in reducing the severity of bradykinesia and dyskinesia in advanced Parkinson’s disease (PD).…
  • 2018 International Congress

    Dyskinesia-hyperpyrexia syndrome (DHS) after sudden interruption of deep brain stimulation and increase of oral dopaminergic therapy: A case report

    F. Dematteis, A. Cormio, C. Fronda, M. Lanotte, M. Zibetti, S. Amarù, L. Lopiano, M. Rizzone (Rivoli, Italy)

    Objective: To report the case of a PD patient treated with bilateral deep brain stimulation of subthalamic nucleus (STN-DBS) who developed DHS after the sudden…
  • 2018 International Congress

    LRRK2 p.Leu119Pro and p.Leu488Pro in a family with neuropathologycally confirmed Parkinson´s disease without Lewy bodies

    L. Vela-DeSojo, J. Hoenicka, P. Pire-Garcia, C. Guerrero, M. Osuna-Lopez, S. Ocaña-Lopez (Alcorcón, (Madrid), Spain)

    Objective: To describe the clinical features, genetic analysis and brain pathology of some members of a family affected by Parkinson´s disease. Background: Mutations of the…
  • 2018 International Congress

    STN deep brain stimulation can directly suppress levodopa-induced dyskinesia in Parkinson’s disease

    J. Li, Y. Zhang (Beijing, China)

    Objective: The study aims to evaluate the effect of bilateral STN-DBS on levodopa-induced peak-dose dyskinesia in patients with PD. Background: Dyskinesia is among the most…
  • « Previous Page
  • 1
  • …
  • 34
  • 35
  • 36
  • 37
  • 38
  • …
  • 49
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley